Equities

Rockwell Medical Inc

Rockwell Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.85
  • Today's Change0.01 / 0.54%
  • Shares traded109.82k
  • 1 Year change-56.06%
  • Beta1.4330
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers around the world. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. It is the supplier of life-sustaining hemodialysis concentrates products to dialysis clinics. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.

  • Revenue in USD (TTM)86.62m
  • Net income in USD-8.42m
  • Incorporated2019
  • Employees237.00
  • Location
    Rockwell Medical Inc30142 WIXOM ROADWIXOM 48393United StatesUSA
  • Phone+1 (248) 960-9009
  • Fax+1 (302) 655-5049
  • Websitehttps://www.rockwellmed.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
RMTI:NAQ since
announced
Transaction
value
Evoqua Water Technologies LLC-Hemodialysis Concentrates BusinessDeal completed11 Jul 202311 Jul 2023Deal completed-70.11%16.00m
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Calcimedica Inc0.00-14.94m52.46m14.00--3.04-----2.64-2.640.001.610.00----0.00-48.34-63.99-66.59-72.71------------0.00------3.51---44.35--
Incannex Healthcare Inc-100.00bn-100.00bn52.70m----3.73----------0.8907-----------54.94---59.47-------1,033.07----0.00--61.923.38-24.35--54.12--
Protara Therapeutics Inc0.00-42.47m52.92m26.00--0.5031-----3.74-3.740.005.110.00----0.00-48.67-37.02-52.23-38.29------------0.00------38.71---17.67--
Aeon Biopharma Inc0.00-485.01m54.38m10.00---------13.04-13.040.00-5.20------0.00-------------------27.67---------631.85------
Immix Biopharma Inc0.00-18.21m54.41m14.00--1.95-----0.9263-0.92630.001.060.00----0.00-77.50---90.46--------------0.00-------87.44------
Anebulo Pharmaceuticals Inc0.00-9.35m54.46m2.00--10.92-----0.3633-0.36330.000.19220.00----0.00-91.51---104.28--------------0.00-------71.89------
Mural Oncology PLC0.00-191.90m54.66m117.00--0.2327-----11.49-11.490.0013.88------0.00--------------------0.00-------9.29------
America Great Health273.71k-873.02k55.09m7.00------201.28-0.00004-0.000040.00001-0.00020.85250.16747.7139,101.43-273.34-543.96----92.45-247.36-320.65-1,193.550.0409-1.46----95.23--84.35------
Reneo Pharmaceuticals Inc0.00-70.71m55.48m8.00--0.6829-----2.17-2.170.002.430.00----0.00-77.06---83.08--------------0.00-------48.95------
Rockwell Medical Inc86.62m-8.42m56.08m237.00--2.65--0.6475-0.3584-0.35843.330.69841.9013.2810.12365,485.20-18.47-46.29-27.53-65.3810.594.66-9.72-36.511.38-3.540.331--14.845.6954.82--76.21--
Lantern Pharma Inc0.00-17.53m57.77m21.00--1.62-----1.62-1.620.003.320.00----0.00-36.82-28.83-39.63-30.17------------0.00-------11.93------
VolitionRX Ltd797.03k-34.91m58.64m110.00------73.57-0.4603-0.46030.0104-0.19010.0425--6.327,245.73-188.25-111.92---196.20-----4,425.95-10,793.31---173.85----153.04---16.68--29.13--
Enzo Biochem Inc33.34m-17.55m59.42m179.00--0.8608--1.78-0.35160.91940.66331.350.40281.664.91186,257.00-21.20-12.21-34.50-15.7943.6637.09-52.63-18.763.16--0.053---4.85-21.01-23.02--7.89--
Data as of Jun 14 2024. Currency figures normalised to Rockwell Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

17.06%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Mar 20242.63m8.67%
The Vanguard Group, Inc.as of 31 Mar 20241.12m3.68%
Perkins Capital Management, Inc.as of 31 Mar 2024348.68k1.15%
Richmond Brothers, Inc.as of 31 Mar 2024322.25k1.06%
Geode Capital Management LLCas of 31 Mar 2024288.76k0.95%
BlackRock Fund Advisorsas of 31 Mar 2024175.16k0.58%
Marshall Wace LLPas of 31 Mar 202497.83k0.32%
SSgA Funds Management, Inc.as of 31 Mar 202474.30k0.25%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202463.84k0.21%
Citadel Securities LLCas of 31 Mar 202457.00k0.19%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.